Clinical manifestations, diagnosis, and treatment of human herpesvirus 6 infection in adults - UpToDate
Clinical manifestations, diagnosis, and treatment of human herpesvirus 6 infection in adults
Clinical manifestations, diagnosis, and treatment of human herpesvirus 6 infection in adults
Author:
Cécile Tremblay, MD
Section Editor:
Martin S Hirsch, MD
Deputy Editor:
Keri K Hall, MD, MS
Literature review current through: Apr 2024.
This topic last updated: Sep 08, 2022.

INTRODUCTION

Human herpesvirus 6 (HHV-6) was first isolated and characterized from patients with lymphoproliferative disorders [1] and was originally named human B-lymphotropic virus. Its name was changed to human herpesvirus 6 as its tropism was further characterized [2].

There are two HHV-6 variants, HHV-6A and HHV-6B. Based on their distinctive biological properties and genome sequences, HHV-6A and HHV-6B have been classified as two distinct herpesvirus species [3]. The vast majority of documented primary infections and reactivation events are due to HHV-6B. HHV-6B infects most children within the first three years of life and, like other herpesviruses, it establishes latency after primary infection. HHV-6B may reactivate in immunocompromised hosts, especially following allogeneic hematopoietic cell transplantation. Little is known about the epidemiology or clinical implications of HHV-6A.

The clinical manifestations, diagnosis, and treatment of HHV-6 infection in adults will be presented here. The virology, pathogenesis, and epidemiology of HHV-6 infection, as well as clinical issues in children, are presented separately; HHV-6 infection in hematopoietic cell transplant recipients is also discussed elsewhere. (See "Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection" and "Human herpesvirus 6 infection in children: Clinical manifestations, diagnosis, and treatment" and "Human herpesvirus 6 infection in hematopoietic cell transplant recipients".)

CLINICAL MANIFESTATIONS

Immunocompetent hosts — HHV-6 infections usually occur during childhood and result in generally mild, self-limited illnesses. Possible disease associations with HHV-6 in immunocompetent adults are not proven other than a few cases of primary infection. (See "Human herpesvirus 6 infection in children: Clinical manifestations, diagnosis, and treatment", section on 'Clinical manifestations'.)

Primary infection — Primary infection in adults is rare. However, a mononucleosis-like syndrome of varying severity with prolonged lymphadenopathy has been described in association with HHV-6 seroconversion in adults [4-6]. Three adults with serologic evidence of HHV-6 infection had mild illnesses in association with bilateral, nontender, anterior, and posterior lymphadenopathy, which persisted for up to three months [5].

Disclaimer: This generalized information is a limited summary of diagnosis, treatment, and/or medication information. It is not meant to be comprehensive and should be used as a tool to help the user understand and/or assess potential diagnostic and treatment options. It does NOT include all information about conditions, treatments, medications, side effects, or risks that may apply to a specific patient. It is not intended to be medical advice or a substitute for the medical advice, diagnosis, or treatment of a health care provider based on the health care provider's examination and assessment of a patient's specific and unique circumstances. Patients must speak with a health care provider for complete information about their health, medical questions, and treatment options, including any risks or benefits regarding use of medications. This information does not endorse any treatments or medications as safe, effective, or approved for treating a specific patient. UpToDate, Inc. and its affiliates disclaim any warranty or liability relating to this information or the use thereof. The use of this information is governed by the Terms of Use, available at https://www.wolterskluwer.com/en/know/clinical-effectiveness-terms. 2024© UpToDate, Inc. and its affiliates and/or licensors. All rights reserved.
Loading
Please wait